<DOC>
	<DOC>NCT00191139</DOC>
	<brief_summary>To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.</brief_summary>
	<brief_title>Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>histologic or cytologic proof of single primary nonsmall cell lung cancer No prior chemotherapy or radiation therapy no prior malignancy pregnancy or breastfeeding serious concomitant systemic disorder unintentional weight loss greater than 10%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>